Profile data is unavailable for this security.
About the company
Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing topical pan-LOX inhibitors in scar revision, keloid scarring and scar prevention post-surgery. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.
- Revenue in AUD (TTM)7.48m
- Net income in AUD-12.26m
- Incorporated1998
- Employees107.00
- LocationSyntara Ltd20 Rodborough RdFRENCHS FOREST 2086AustraliaAUS
- Phone+61 29454-7200
- Fax+61 29451-3622
- Websitehttps://www.pharmaxis.com.au/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Algorae Pharmaceuticals Ltd | 141.05k | -802.96k | 27.21m | -- | -- | 12.11 | -- | 192.90 | -0.0005 | -0.0005 | 0.00008 | 0.0013 | 0.0505 | -- | 3.38 | -- | -28.72 | -51.95 | -30.63 | -56.76 | -- | -- | -569.27 | -1,452.78 | -- | -- | 0.00 | -- | 12.66 | -23.93 | 61.68 | -- | -- | -- |
| Argenica Therapeutics Ltd | 332.69k | -9.80m | 28.90m | -- | -- | 8.39 | -- | 86.88 | -0.0762 | -0.0762 | 0.0026 | 0.0268 | 0.0323 | -- | 1.79 | -- | -95.10 | -47.11 | -117.81 | -55.90 | -- | -- | -2,945.67 | -2,938.71 | -- | -40,666.84 | 0.00 | -- | 166.93 | 359.61 | -30.86 | -- | -- | -- |
| Neuroscientific Biopharmaceuticals Ltd | 166.08k | -1.85m | 33.26m | -- | -- | 1.98 | -- | 200.25 | -0.0126 | -0.0126 | 0.0011 | 0.0506 | 0.0148 | -- | 2.17 | -- | -16.48 | -37.13 | -16.65 | -40.11 | -- | -- | -1,111.22 | -185.57 | -- | -746.17 | 0.00 | -- | -93.05 | 16.84 | -669.23 | -- | -- | -- |
| Anteotech Ltd | 1.03m | -6.76m | 35.68m | 40.00 | -- | 10.31 | -- | 34.72 | -0.0025 | -0.0025 | 0.0004 | 0.0012 | 0.1299 | -- | 6.90 | -- | -85.41 | -76.84 | -106.22 | -87.65 | -- | -- | -657.69 | -1,253.69 | -- | -- | 0.3835 | -- | 99.60 | 27.97 | 23.89 | -- | -4.02 | -- |
| Emyria Ltd | 1.39m | -3.14m | 41.13m | -- | -- | 5.88 | -- | 29.49 | -0.0069 | -0.0069 | 0.0031 | 0.0087 | 0.2316 | -- | 40.72 | -- | -52.19 | -82.51 | -69.83 | -106.69 | 1.76 | -17.98 | -225.33 | -355.61 | -- | -22.44 | 0.1037 | -- | -36.68 | 6.60 | 72.57 | -- | -41.45 | -- |
| Proteomics International LaboratoriesLtd | 3.31m | -8.11m | 52.03m | -- | -- | 3.91 | -- | 15.71 | -0.0605 | -0.0605 | 0.0247 | 0.0805 | 0.2582 | -- | 12.02 | -- | -63.57 | -63.62 | -68.88 | -71.91 | -- | -- | -246.18 | -222.10 | -- | -- | 0.021 | -- | 1.34 | 15.81 | -27.27 | -- | -54.88 | -- |
| Syntara Ltd | 7.48m | -12.26m | 52.27m | 107.00 | -- | 3.25 | -- | 6.99 | -0.0084 | -0.0054 | 0.0051 | 0.0099 | 0.4701 | -- | 2.53 | -- | -77.03 | -36.39 | -116.54 | -50.26 | -- | -- | -163.86 | -78.37 | -- | -953.38 | 0.0052 | -- | 37.80 | -9.83 | 10.31 | -- | -- | -- |
| Entropy Neurodynamics Ltd | 1.63m | -4.74m | 53.18m | -- | -- | 6.89 | -- | 32.59 | -0.0031 | -0.0031 | 0.001 | 0.0049 | 0.2271 | -- | 0.9714 | -- | -65.94 | -- | -77.78 | -- | -- | -- | -290.41 | -- | -- | -876.73 | 0.0773 | -- | -- | -10.25 | -- | -- | -26.73 | -- |
| Clever Culture Systems Ltd | 6.23m | -744.00k | 56.61m | 17.00 | -- | 7.05 | -- | 9.09 | -0.0004 | -0.0004 | 0.0032 | 0.0037 | 0.5403 | 0.5939 | 3.12 | -- | -6.45 | -36.73 | -8.33 | -42.00 | 80.83 | -- | -11.94 | -281.21 | 1.94 | -7.62 | 0.1406 | -- | 397.86 | 30.08 | 145.03 | -- | 24.71 | -- |
| Amplia Therapeutics Ltd | 5.01m | -7.93m | 61.57m | 1.00 | -- | 1.43 | -- | 12.30 | -0.0204 | -0.0204 | 0.0128 | 0.0837 | 0.1705 | -- | 1.28 | -- | -27.01 | -27.37 | -28.31 | -30.38 | -- | -- | -158.46 | -180.53 | -- | -- | 0.0088 | -- | -15.01 | 156.11 | -45.93 | -- | -- | -- |
| Rhythm Biosciences Ltd | 1.72m | -6.68m | 65.49m | -- | -- | 31.45 | -- | 38.05 | -0.0228 | -0.0228 | 0.0057 | 0.0064 | 0.3812 | 55.37 | 24.28 | -- | -147.85 | -146.24 | -188.09 | -197.40 | -157.89 | 22.48 | -387.87 | -287.42 | 2.23 | -83.53 | 0.1091 | -- | 90.87 | 135.14 | 44.15 | -- | -12.61 | -- |
| Imugene Ltd | 0.00 | -69.02m | 69.13m | 0.00 | -- | 1.05 | -- | -- | -0.3161 | -0.3161 | 0.00 | 0.205 | 0.00 | -- | -- | -- | -58.75 | -48.72 | -75.21 | -53.73 | -- | -- | -- | -- | -- | -- | 0.1913 | -- | -- | -- | 53.89 | -- | 38.40 | -- |
| Prescient Therapeutics Ltd | 34.87k | -8.86m | 69.40m | 3.00 | -- | 4.09 | -- | 1,990.25 | -0.01 | -0.01 | 0.00004 | 0.0161 | 0.002 | -- | 0.165 | -- | -50.54 | -31.70 | -53.95 | -34.33 | -- | -- | -25,409.32 | -2,146.75 | -- | -- | 0.0158 | -- | -67.19 | 26.24 | 11.11 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Syntara Ltd's reporting currency: Australian Dollar AUD
17.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Platinum Investment Management Ltd.as of 21 May 2025 | 172.16m | 10.55% |
| Harper Bernays Ltd.as of 22 Aug 2024 | 57.61m | 3.53% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 42.62m | 2.61% |
| Wilson Asset Management (International) Pty Ltd.as of 30 Jun 2025 | 17.24m | 1.06% |
| DFA Australia Ltd.as of 31 Jan 2026 | 530.33k | 0.03% |
| BVF Partners LPas of 20 Jun 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
